---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000059"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-09-29T12:01:22+00:00"
generated_at: "2026-10-12T13:42:41.275848+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Keros to receive $20M Takeda milestone after first patient dosed in Phase 3 ELRiSE MF trial

## Summary
- Keros expects a $20M development milestone from Takeda after the first patient was dosed in ELRiSE MF, a Phase 3 trial of elritercept vs placebo in myelofibrosis with anemia on ruxolitinib.
- The Takeda license, effective January 16, 2025, covers development, manufacturing, and commercialization of elritercept worldwide excluding mainland China, Hong Kong, and Macau.
- Keros received a $200M upfront cash payment in February 2025 and can earn development, commercial, and sales milestones potentially exceeding $1.1B plus tiered royalties.
- Keros plans to distribute 25% of net cash proceeds from the $20M milestone to stockholders following receipt.

## SEC filing metadata
- accession: 0001664710-26-000059
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-09-29T12:01:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000059/0001664710-26-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000059/kros-20260929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000059
- JSON: https://secwatch.observer/filing/0001664710-26-000059.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.